EXPE
Expedia Group, Inc.
EXPE has the edge over LCID overall, supported by stronger valuation and lower modeled downside.
LCID
Lucid Group, Inc.
LCID's outlook is improving, though it still trails on the overall score.
EXPE Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Strong |
EXPE's revenue, profitability, cash flow and balance sheet are all currently healthy.
LCID Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Weak | |
| Weak | |
| Unavailable |
LCID's revenue is currently healthy, but its profitability and cash flow are weak. There isn't enough data to rate its balance sheet.
EXPE PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 11x | $261 | — |
| Current | 15x | $261 | — |
| Cheap | 19x | $330 | +26% |
| Fair | 25x | $428 | +64% |
| Expensive | 41x | $701 | +169% |
Historical ranges are pointers, not guarantees.
EXPE's PE is in its cheap range at 15x. If earnings grow as analysts expect, today's price would be 11x next year's earnings.
LCID PE Valuation
LCID has no meaningful PE right now: it lost money over the past year.
EXPE Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Growth | |
| Strongly improving | |
| Moderate | |
| Low |
Analysts expect earnings and revenue growth for EXPE, with profitability improving. However, they disagree widely on these estimates.
LCID Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect LCID's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
EXPE Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $24.30 | +42% |
| Q3 2026 | $17.09 | +65% |
| Q2 2026 | $16.00 | +99% |
| Q1 2026 | $11.32 | +35% |
| Q4 2025 | $9.81 | +9.6% |
| Q3 2025 | $10.35 | +34% |
| Q2 2025 | $8.06 | +46% |
| Q1 2025 | $8.38 | +59% |
| Q4 2024 | $8.95 | +69% |
EXPE has the edge over LCID on earnings quality, reporting a profit while its opponent remains loss making.
LCID Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$13.08 | -$2.57 |
| Q2 2026 | -$13.65 | -$2.35 |
| Q1 2026 | -$13.15 | -$1.25 |
| Q4 2025 | -$12.09 | +$0.41 |
| Q3 2025 | -$10.51 | +$2.49 |
| Q2 2025 | -$11.30 | +$0.40 |
| Q1 2025 | -$11.90 | +$0.40 |
| Q4 2024 | -$12.50 | +$1.10 |
LCID is still losing money, but less than at its worst: $13.08 per share over the past year, against $16.50 at its worst in mid-2023.
EXPE Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $4.9B | +12% |
| Q2 2026 | $4.3B | +14% |
| Q1 2026 | $3.4B | +15% |
| Q4 2025 | $3.5B | +11% |
| Q3 2025 | $4.4B | +8.7% |
| Q2 2025 | $3.8B | +6.4% |
| Q1 2025 | $3B | +3.4% |
| Q4 2024 | $3.2B | +10% |
EXPE's revenue has grown year over year for 22 quarters in a row: $4.9B last quarter, up 12% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 27% | +3.4 points |
| Q2 2026 | 19% | +5.7 points |
| Q1 2026 | 7.3% | +9.7 points |
| Q4 2025 | 12% | +5.1 points |
| Q3 2025 | 23% | +4.7 points |
| Q2 2025 | 13% | +0.1 points |
| Q1 2025 | -2.3% | +1.5 points |
| Q4 2024 | 6.8% | +3.2 points |
EXPE has the edge over LCID on profitability, with a higher operating margin.
LCID Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $350.3M | +4.1% |
| Q2 2026 | $405.3M | +56% |
| Q1 2026 | $282.5M | +20% |
| Q4 2025 | $522.7M | +123% |
| Q3 2025 | $336.6M | +68% |
| Q2 2025 | $259.4M | +29% |
| Q1 2025 | $235M | +36% |
| Q4 2024 | $234.5M | +49% |
LCID has the edge over EXPE on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -245% | +35 points |
| Q2 2026 | -267% | +43 points |
| Q1 2026 | -350% | -56 points |
| Q4 2025 | -204% | +109 points |
| Q3 2025 | -280% | +105 points |
| Q2 2025 | -310% | +83 points |
| Q1 2025 | -294% | +128 points |
| Q4 2024 | -313% | +156 points |
LCID's operating margin was −245% last quarter, up 35 points from the same quarter a year ago, near the top of its range since 2020.
EXPE Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.4B | -$713M |
| Q2 2026 | $1.3B | +39% |
| Q1 2026 | $3.7B | +36% |
| Q4 2025 | $119M | +1600% |
| Q3 2025 | -$686M | +$1B |
| Q2 2025 | $921M | -30% |
| Q1 2025 | $2.8B | +2% |
| Q4 2024 | $7M | +$422M |
EXPE has the edge over LCID on cash generation, producing positive trailing cash flow while its opponent burns cash.
LCID Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1B | -$84.2M |
| Q2 2026 | -$1.5B | -$463.2M |
| Q1 2026 | -$1.4B | -$849M |
| Q4 2025 | -$1.2B | -$417.1M |
| Q3 2025 | -$955.5M | -$333M |
| Q2 2025 | -$1B | -$271.6M |
| Q1 2025 | -$589.9M | +$125.1M |
| Q4 2024 | -$824.8M | -$77.6M |
LCID has burned cash in almost every quarter: −$5.2B over the past year, against −$3.4B the year before.
EXPE Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.2% | -272K shares |
| 1 year | -6.7% | -8.7M shares |
| 3 years | -17% | -25.5M shares |
| 5 years | -24% | -38.2M shares |
| Available history | -18% | -27.6M shares |
EXPE has the edge over LCID on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $669M |
| Q2 2026 | $270M |
| Q1 2026 | $788M |
| Q4 2025 | $327M |
| Q3 2025 | $531M |
| Q2 2025 | $688M |
| Q1 2025 | $384M |
| Q4 2024 | $198M |
EXPE spent $2.1B buying back its own shares over the past year, up 14% from the year before.
LCID Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.3% | +12.5M shares |
| 1 year | +26% | +82.4M shares |
| 3 years | +73% | +166M shares |
LCID has 395M diluted shares, up 26% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | $2.2M |
| Q1 2020 | — |
EXPE Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 0.1x | Very low |
| Q2 2026 | -0.4x | Net Cash |
| Q1 2026 | -0.4x | Net Cash |
| Q4 2025 | 0.3x | Very low |
| Q3 2025 | 0.2x | Very low |
| Q2 2025 | -0.0x | Net Cash |
| Q1 2025 | 0.2x | Very low |
| Q4 2024 | 1.0x | Very low |
EXPE's net debt is less than a year of its operating earnings (EBITDA).
LCID Net Leverage
LCID's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
EXPE Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 46.3 | Neutral |
| Stochastic | 20.0 | Neutral |
EXPE's weekly RSI is 46 (neutral) and its Stochastic is 20 (neutral).
LCID Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 32.9 | Neutral |
| Stochastic | 7.1 | Oversold |
LCID's weekly RSI is 33 (neutral) and its Stochastic is 7 (oversold).
EXPE PE vs Consumer Cyclical Sector
| Metric | EXPE | Sector median | Relative |
|---|---|---|---|
| PE | 15x | 18x | 15% below |
| PE % | 1 | 47 | 46 pts below |
EXPE is trading at 15x earnings, a 15% discount to the Consumer Cyclical sector's median of 18x.
LCID PE vs Consumer Cyclical Sector
LCID has no meaningful PE right now: it lost money over the past year.
EXPE Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $273.5 | 4.5% below |
| 20 week MA | $285.2 | 8.5% below |
| 50 week MA | $261.9 | 0.3% below |
| 100 week MA | $226.8 | 15% above |
| 200 week MA | $176.0 | 48% above |
EXPE has the edge over LCID on trend strength, trading above more of its moving averages.
LCID Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $3.53 | 7.9% below |
| 20 week MA | $4.88 | 33% below |
| 50 week MA | $7.33 | 56% below |
| 100 week MA | $15.4 | 79% below |
| 200 week MA | $31.9 | 90% below |
LCID is in a downtrend: it's below all five of its weekly moving averages, and 90% below its 200-week average.
EXPE Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $108.3 | $127.0 | +17% |
| 2021 | $127.0 | $183.8 | +45% |
| 2022 | $183.8 | $86.4 | -53% |
| 2023 | $86.4 | $151.8 | +76% |
| 2024 | $151.8 | $186.1 | +23% |
| 2025 | $186.1 | $287.6 | +55% |
| 2026 YTD | $287.6 | $261.1 | -9.2% |
EXPE has the edge over LCID on returns for 2026, with the stronger performance.
LCID Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $98.9 | $100.4 | +1.5% |
| 2021 | $100.4 | $376.4 | +275% |
| 2022 | $376.4 | $67.0 | -82% |
| 2023 | $67.0 | $42.1 | -37% |
| 2024 | $42.1 | $32.0 | -24% |
| 2025 | $32.0 | $11.4 | -64% |
| 2026 YTD | $11.4 | $3.25 | -72% |
LCID has finished four years in a row lower, and it's down 72% so far in 2026.